AEON Biopharma, Inc. Quarterly Deferred Tax Assets, Net of Valuation Allowance in USD from Q4 2022 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
AEON Biopharma, Inc. quarterly Deferred Tax Assets, Net of Valuation Allowance history and growth rate from Q4 2022 to Q4 2023.
  • AEON Biopharma, Inc. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending December 31, 2023 was $153K, a 32.6% decline year-over-year.
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $153K -$74K -32.6% Dec 31, 2023 10-K/A 2024-05-14
Q4 2022 $227K Dec 31, 2022 10-K/A 2024-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.